NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.

Last week Fluoguide announced a collaboration with Intuitive Surgical, a USD 140 billion company working with robot-assisted surgeries, seeking to advance FG001. Furthermore, there were insiders buying Acarix, new share buybacks in Genmab, as well as updates on rights issues in Biosergen and Curasight. The Nordic Healthcare Index (KPHC) continues to move in sync with the KPNGX index. As always, we also present the top 3 Nordic healthcare stocks in the past week.

4 of the 21 Danish companies had a positive share price development the past week and 8 companies have had a positive share price performance year-to-date. Y-mAbs Therapeutics is still the best-performing Danish healthcare stock year-to-date with a 116% return, closely followed by Gubra, and DanCann Pharma was the best Nordic healthcare investment last week.

---

Stay tuned to the developments of impact companies and stocks in the Nordics with the NORDIC | IMPACT newsletter that helps you invest more sustainably in the businesses of tomorrow.

---

DANISH COMPANY NEWS

Acarix

CEO purchases shares in Acarix (Link)

Ascendis Pharma

No news the past week

Biosergen

Members of the board of directors and management subscribe in ongoing rights issue (Link)

Cessatech

Annual General Meeting – 27 March 2024 (Link)

CS Medica

No news the past week

Curasight

Curasight not to proceed with rights issue; evaluating alternative financing opportunities (Link)

Read our comments on the news here. (in Danish)

Evaxion Biotech

No news the past week

ExpreS2ion

No news the past week

Fluoguide

FluoGuide enters collaboration within robot assisted head and neck cancer surgery with Intuitive Surgical, a world leading robotic-assisted surgery company (Link)

Genmab

Genmab Announces Initiation of Share Buy-Back Program (Link)

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons (Link)

Transactions in connection with share buy-back program (Link)

Gubra

No news the past week

Initiator Pharma

No news the past week

IO Biotech

No news the past week

Pila Pharma

No news the past week

Saniona

No news the past week

Scandion Oncology

Annual Report 2023 (Link)

SynAct Pharma

No news the past week

ViroGates

No news the past week

Zealand Pharma

New Employee Elected Directors to the Board of Zealand Pharma A/S (Link)

Y-mAbs Therapeutics

Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer (Link)

2cureX

2CUREX AB provides an update on its financial position and current operations (Link)

SELECTED CASES

SHARE PRICE DEVELOPMENTS – Danish stocks

On average, the Danish biotech and healthcare stocks delivered a negative share price performance of the past week of 4.1%. Fluoguide did well after they entered into a collaboration with Intuitive Surgical, a USD 140 billion company working with robot-assisted surgeries, where the goal is to develop FG001 for tutor imaging and more. It is highly positive for the company to be associated with Intuitive Surgical, and it is interesting what the collaboration can bring.

Members of the management and board of directors in Biosergen chose to participate in the ongoing rights issue, while Curasight announced not to proceed with the rights issue due to low participation. Curasight now seeks other financing alternatives. Finally, Y-mAbs Therapeutics’ CFO resigned, there was an insider buy in Acarix and Genmab initiated a new buyback program.

The best stocks year-to-date are Y-mAbs Therapeutics, Zealand Pharma, and Gubra with 87-116% increases after ten weeks of trading. Overall the Danish biotech and healthcare stocks are in positive territory this year with a year-to-date return of 3.8%. 2cureX AB is currently dropping 76% on its financial and operational update. The drop in the share price is not a part of the table below as it only counts last week’s performance.

Overview of share price developments the past week, year-to-date, and last twelve months

NORDIC BIOTECH & HEALTHCARE DEVELOPMENTS

In the past week, the all-Nordic index Kapital Partner Nordic Healthcare Index (KPHC) dropped 1% to 60.54. The index was recovering from its all-time low in October of 57.12 but has since been on a downward trajectory. In the past 12 months, the index has significantly underperformed relative to large caps, while the venture/small cap Kapital Partner Nordic Growth Exchanges index (KPNGX) has followed the KPHC index’s downward trajectory down around 20%.

The index development for Kapital Partner Healthcare Index the past 12 months

35-159% in weekly return for the three best-performing Nordic biotech & healthcare stocks the past week

DanCann Pharma A/S AB (159%) (Nordnet) focuses on discovering, developing, producing, and commercializing novel cannabinoid drugs in a wide range of disease areas. The company produces and distributes prescription and over-the-counter (OTC) medicines, mainly focused on pain patients with alternative needs and treatment of their disease, covered by the Danish pilot program for medicinal cannabis.).

Xbrane Biopharma AB (44%) (Nordnet)  specializes in research and development of drugs for the treatment of critical illnesses. Today, the business is focused on research in microspherical technology and in the development of protein molecules. The products are used in the treatment of prostate cancer and endometriosis, as well as in rare and serious eye diseases. The subscription period for the company’s current rights issue finished last week with a subscription of 98.4%.

Spermosens AB (35%) (Nordnet) specializes in the development of medical devices. The product portfolio is broad and includes products for male infertility and individually tailored fertility treatments. Research and development is conducted via its own technological platform that analyzes sperm quality, which is further used for medical data and potential fertilization.

Sources: Refinitiv Eikon, Cision, Nordnet & company websites